Keytruda, a cancer drug manufactured by Merck & Co., was approved by the Food and Drug Administration (FDA) on September 4, 2014 [1]. The drug, which is a programmed death receptor-1 (PD-1) inhibitor, was initially approved for the treatment of advanced melanoma [1].

According to DrugPatentWatch.com, Keytruda's patent expiration date is in December 2028 [2]. This means that generic versions of the drug may become available in the United States market after this date.

It is important to note that the FDA approval of Keytruda was a significant milestone in cancer treatment. The drug has since been approved for the treatment of several other types of cancer, including non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, and microsatellite instability-high (MSI-H) cancer [1].

In summary, Keytruda was approved by the FDA on September 4, 2014, for the treatment of advanced melanoma. The drug has since been approved for the treatment of several other types of cancer. Keytruda's patent is set to expire in December 2028.

Sources:

* [1] U.S. Food and Drug Administration. (2022). Keytruda. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/keytruda-pembrolizumab-injections-solution>.
* [2] DrugPatentWatch.com. (2022). Keytruda (pembrolizumab) Patent Expiration & Drug Price. <https://www.drugpatentwatch.com/drugs/keytruda>.